证券代码：603233 证券简称：大参林 公告编号：2025-051 大参林医药集团股份有限公司 关于 2020 年员工持股计划延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 大参林医药集团股份有限公司（以下简称"公司"）2020 年员工持股计划（以 下简称"员工持股计划"）的存续期将于 2025 年 12 月 3 日到期，2025 年 8 月 28 日公司召开了第四届董事会第二十七次会议，审议通过了《关于公司 2020 年 员工持股计划延期的议案》，同意将公司 2020 年员工持股计划存续期延长 12 个月，即延长至 2026 年 12 月 3 日。现将相关情况提示公告如下： 一、员工持股计划的基本情况 1、经公司 2020 年 10 月 9 日召开的第三届董事会第九次会议及 2020 年 10 月 26 日召开的 2020 年第四次临时股东大会，审议通过了《关于<大参林医药集 团股份有限公司 2020 年员工持股计划（草案）>及其摘要的议案》及相关议案， 同意实施公司 2020 年员工持股计划，股份来源于 ...

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion in the pharmaceutical industry, particularly for Chinese companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring discussions and presentations from industry leaders [1]. Pharmaceutical Main Forum - The main forum will include several roundtable discussions, such as: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Blockbuster" [4]. - "Next-Generation Weight Loss Drug Development Hotspots and China's Pipeline Competitiveness" [5]. - "Which Disease and Technology Areas in Pharmaceuticals are Worth Expecting for Going Global?" [5]. - "The New Cycle of Chinese Innovative Drugs Under Global Competition: Breaking Through from R&D to Commercialization" [5]. - "Technological Upgrades: Exploring the Next Wave of Drug Development Platforms" [5]. - "The Future is Here: Dialogue on the New World of Brain-Machine Interfaces" [6]. - "Innovation Going Global" [6]. TMT Sub-Forum - The TMT sub-forum will cover topics such as: - "Outlook for the Two-Dimensional Animation Industry" [6]. - "How AI Disrupts the Game Industry Structure" [6]. - "The Future of AI Companion Toys" [6]. - "Innovations and Explorations in AI Immersive Video" [6]. - "ASIC and Internet Giants' Innovations" [7]. - "Demonstrations and Introductions of Brain-Machine Interface Products" [7]. Additional Discussions - The second day will feature discussions on AI's impact on finance and healthcare, including: - "AI Infrastructure Development" [9]. - "Current Status and Outlook of Direct Satellite Communication Technology in Domestic Mobile Phones" [9]. - "Future Development of AI Network Architecture" [9]. Industry Participation - The event will see participation from numerous leading companies in pharmaceuticals, medical devices, and technology sectors, including major players in drug development, medical services, and internet healthcare [13][15].

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

Core Viewpoint - The well-known retail pharmacy chain, Lao Bai Xing, is experiencing increasing losses despite expanding its store network, raising concerns about its profitability and future strategies [2][3]. Financial Performance - In the first half of 2025, Lao Bai Xing reported a revenue of 10.774 billion yuan, a year-on-year decrease of 1.51%, and a net profit attributable to shareholders of 398 million yuan, down 20.86% year-on-year [2]. - The gross profit margin for the first half of 2025 was 33.08%, a decline of 1.24% compared to the previous year [3]. - The company added 108 new stores, with a net increase of 305 franchise stores and a net decrease of 197 self-operated stores [3]. Market Competition - The decline in net profit is attributed to a drop in single-store revenue and intensified competition among pharmacies, leading to frequent promotions and price wars that compress profit margins [3]. - In the first quarter of 2025, the number of retail pharmacies in China continued to decrease, with a net reduction of approximately 3,000 stores, bringing the total below 700,000 [3]. Industry Trends - Major retail pharmacy companies, including Lao Bai Xing, have reported significant declines in net profit for 2024, with year-on-year decreases of 44.13% for Lao Bai Xing and 59.83% for Guoyao Yizhi [4]. - The trend of declining profits has persisted into the first quarter of 2025, with Lao Bai Xing's net profit down 21.98% [4]. Financial Risks - Lao Bai Xing's financial pressure is increasing, with short-term non-current liabilities amounting to 1.093 billion yuan and long-term borrowings of 1.321 billion yuan as of the first half of 2025 [6]. - The company's goodwill has surged to 5.763 billion yuan, while its net assets stand at only 6.733 billion yuan, raising concerns about potential goodwill impairment risks [6]. Management Insights - The decline in net profit is primarily due to the increase in new store numbers, the performance of new stores still in the growth phase, and the company's recognition of goodwill impairment losses [7]. Shareholder Actions - Following the release of poor financial results, Lao Bai Xing's controlling shareholder, Yao Yi Group, announced a plan to reduce its stake by up to 22.8029 million shares, approximately 3% of the total share capital, aiming to adjust its asset and financing structure [9]. - The group has engaged in multiple rounds of share pledging, with 62.04% of its shares pledged as of June 30, 2025, indicating a reliance on this financing method to alleviate short-term financial pressures [10].

Core Viewpoint - The well-known retail pharmacy chain, Lao Bai Xing, is experiencing increasing losses despite expanding its store network, raising concerns about its profitability and future strategies [2][3]. Financial Performance - In the first half of 2025, Lao Bai Xing reported revenue of 10.774 billion yuan, a year-on-year decrease of 1.51%, and a net profit attributable to shareholders of 398 million yuan, down 20.86% year-on-year [2]. - The company's gross margin for the same period was 33.08%, a decline of 1.24% compared to the previous year [3]. - The retail revenue from pharmaceuticals decreased by 2.30% year-on-year, with a gross margin drop of 1.07% [3]. Store Expansion and Market Competition - Lao Bai Xing added 108 new stores in the first half of 2025, with a net increase of 305 franchise stores and a decrease of 197 direct-operated stores [3]. - The competitive landscape among pharmacies is intensifying, leading to frequent promotions and price wars that compress profit margins [3]. - The total number of retail pharmacies in China has been declining, with a net reduction of approximately 3,000 stores in the first quarter of 2025, bringing the total below 700,000 [3]. Debt and Goodwill Concerns - Lao Bai Xing's short-term non-current liabilities reached 1.093 billion yuan, and long-term borrowings amounted to 1.321 billion yuan in the first half of 2025 [6]. - The company's goodwill has surged to 5.763 billion yuan, while its net assets stood at 6.733 billion yuan, raising concerns about potential goodwill impairment risks if future acquisitions underperform [6]. Shareholder Actions - Following the release of disappointing financial results, Lao Bai Xing's controlling shareholder, the Pharmaceutical Group, announced a plan to reduce its stake by up to 22.8029 million shares, representing 3% of the total share capital, potentially raising around 451 million yuan [8]. - The Pharmaceutical Group has engaged in multiple rounds of share pledging and unpledging, with 62.04% of its shares pledged as of June 30, 2025, indicating a strategy to manage short-term liquidity pressures [9].

Core Viewpoint - The performance of listed chain pharmacies remains challenging in the first half of 2025, with some signs of improvement, as companies adapt to a new phase of structural growth in the pharmaceutical retail industry [1][2][3]. Financial Performance - In the first half of 2025, the company reported revenue of 10.774 billion yuan, a year-on-year decrease of 1.51%, and a net profit attributable to shareholders of 398 million yuan, down 20.86% [1][2]. - The decline in net profit is attributed to an increase in the proportion of new retail business sales, which led to a decrease in gross margin, as well as rising R&D expenses [2]. - Compared to the first quarter, the second quarter showed improvement, with revenue decline narrowing to 1.14% from 1.88% in the first quarter, and retail revenue growing by 0.20% [2]. Store Expansion and Business Model - The company has shifted its focus from rapid store expansion to structural adjustments for high-quality growth, with a net increase of only 108 stores in the first half of 2025, including a rare net decrease in direct stores [3][5]. - As of June 30, 2025, the company operated 15,385 stores, with 9,784 direct stores and 5,601 franchise stores [3]. Diversification and Cost Efficiency - The company is emphasizing diversification, particularly in non-pharmaceutical products, with a focus on health services and a significant increase in the proportion of franchise stores [5][6]. - The company aims to reduce costs and improve efficiency, achieving a 165.92% year-on-year increase in net cash flow from operating activities, primarily due to reduced procurement payments and lower wage expenses [7][8]. Technological Integration - The company is investing heavily in AI and big data to enhance operational efficiency and customer service, with R&D expenses surging by 8686.48% to 36.89 million yuan in the first half of 2025 [8]. - The company has developed multiple AI dialogue assistants to optimize various business operations and improve customer service [8]. Industry Outlook - The retail pharmacy industry is entering a new phase of structural growth, moving away from broad-based expansion to identifying specific growth opportunities in niche markets [1][3]. - The industry is expected to experience a "Matthew Effect," where stronger players will continue to dominate, necessitating a shift in value positioning from mere product sales to comprehensive health solutions [9].

Core Viewpoint - The financial performance of the leading chain pharmacy, Lao Bai Xing, has shown a decline in both revenue and net profit for the first half of 2025, indicating challenges in the retail pharmacy sector amid increased competition and operational changes [1][3]. Financial Performance - In the first half of 2025, the company achieved revenue of 10.774 billion yuan, a year-on-year decrease of 1.51% [1]. - The net profit attributable to shareholders was 398 million yuan, down 20.86% compared to the previous year [1]. - The gross profit margin for the main business was 33.08%, a decline of 1.24 percentage points year-on-year [1]. Store Expansion and Market Strategy - The company is actively expanding into lower-tier markets, with 87% of new stores opened in cities below the prefecture level during the first half of 2025 [2]. - As of the end of the reporting period, stores in cities below the prefecture level accounted for 77% of the total store count [2]. - The number of franchise stores increased by 457, reaching a total of 5,601 [2]. Management Changes - The company experienced significant management turnover in 2025, with both the president and vice president resigning [2]. - The founder, Xie Zilong, has taken on the roles of both chairman and president following these departures [2]. - The high turnover rate in the executive team has raised concerns about stability, with multiple resignations noted in recent years [2]. Overall Industry Context - The overall performance of major listed chain pharmacies, including Lao Bai Xing, has been declining, with a notable drop in revenue and net profit for the year 2024 [3]. - The company’s major shareholder announced a significant share reduction plan, which was partially executed before being terminated [3]. - From June 20 to July 30, 2025, the major shareholder reduced their holdings by 18.11 million shares, amounting to 2.38% of the total shares, generating over 340 million yuan in cash [3].

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

广东开出上万家店的连锁药业大参林，老板被刑拘了要卖股票还债，公司也被处罚，私募基金股东也偷偷减持。 更不用说，行业内7家连锁药店上市公司的财报显示，连续多年净利润增长齐刷刷在去年掉头，药店行业的数据也显示，去年合计关店3.9万家，而且四个 季度内，关店速度是递增的。 行业拐点来临，曾经狂赚钱的暴利生意，真的走到头了吗？ 以前这药店，可是一条街就能开好几家的暴利生意，但是从去年开始这所谓的暴利也不太行了。即便是上市的连锁药店，也避免不了这个结局。行业拐点 来临，曾经狂赚钱的暴利生意，真的走到头了吗？ 山东本地连锁药店龙头，被老板和高管们连续多次减持，一季度门店也关了119家。 连锁药店撑不住了？老板和高管们一通减持 连锁药店漱玉平民大药房，最近被老板和高管们一通减持： 虽然实控人李文杰是第一次减持漱玉平民的股，但在一年内，这已经是漱玉平民的第四轮股东减持潮。 2024年9月25日，漱玉平民公告称，股东阿里健康(持股比例8.47%)拟减持公司股份不超过12070642股，占公司总股本的3%，减持原因为自身资金需求。 阿里健康准备出货没两个月，漱玉平民马上又迎来第二轮减持。 2024年11月6日，漱玉平民公告，公司 ...

Company Overview - Dazhonglin's stock price closed at 17.27 yuan on August 21, 2025, with a 0.52% increase from the previous trading day and a trading volume of 128 million yuan [1] - The company primarily engages in pharmaceutical retail chain operations, covering categories such as drugs, medical devices, and health products [1] - As of Q1 2025, Dazhonglin has over 16,500 stores, expanding through both direct and franchise models [1] Industry Trends - The retail pharmacy industry is currently undergoing an adjustment period, with approximately 3,000 pharmacies closing nationwide in Q1 2025, leading to increased industry concentration [1] - Dazhonglin plans to accelerate its franchise business to attract small and medium-sized chains and independent pharmacies, aiming to enhance regional market share [1] - The trend towards innovative DTP pharmacies and diversified health services is seen as a direction for industry transformation, which may benefit Dazhonglin [1] Financial Insights - On August 21, 2025, the net outflow of main funds was 10.7369 million yuan, with a cumulative net outflow of 5.2670 million yuan over the past five days [1]